These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 33227982)

  • 1. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer.
    Vernocchi P; Gili T; Conte F; Del Chierico F; Conta G; Miccheli A; Botticelli A; Paci P; Caldarelli G; Nuti M; Marchetti P; Putignani L
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
    Botticelli A; Vernocchi P; Marini F; Quagliariello A; Cerbelli B; Reddel S; Del Chierico F; Di Pietro F; Giusti R; Tomassini A; Giampaoli O; Miccheli A; Zizzari IG; Nuti M; Putignani L; Marchetti P
    J Transl Med; 2020 Feb; 18(1):49. PubMed ID: 32014010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.
    Derosa L; Iebba V; Silva CAC; Piccinno G; Wu G; Lordello L; Routy B; Zhao N; Thelemaque C; Birebent R; Marmorino F; Fidelle M; Messaoudene M; Thomas AM; Zalcman G; Friard S; Mazieres J; Audigier-Valette C; Sibilot DM; Goldwasser F; Scherpereel A; Pegliasco H; Ghiringhelli F; Bouchard N; Sow C; Darik I; Zoppi S; Ly P; Reni A; Daillère R; Deutsch E; Lee KA; Bolte LA; Björk JR; Weersma RK; Barlesi F; Padilha L; Finzel A; Isaksen ML; Escudier B; Albiges L; Planchard D; André F; Cremolini C; Martinez S; Besse B; Zhao L; Segata N; Wojcik J; Kroemer G; Zitvogel L
    Cell; 2024 Jun; 187(13):3373-3389.e16. PubMed ID: 38906102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.
    Nucera F; Ruggeri P; Spagnolo CC; Santarpia M; Ieni A; Monaco F; Tuccari G; Pioggia G; Gangemi S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota and its metabolites in non-small cell lung cancer and brain metastasis: from alteration to potential microbial markers and drug targets.
    Jiang H; Zeng W; Zhang X; Li Y; Wang Y; Peng A; Cao D
    Front Cell Infect Microbiol; 2023; 13():1211855. PubMed ID: 38304459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma: Study protocol for case-control observational trial.
    Bingula R; Filaire M; Radosevic-Robin N; Berthon JY; Bernalier-Donadille A; Vasson MP; Thivat E; Kwiatkowski F; Filaire E
    Medicine (Baltimore); 2018 Dec; 97(50):e13676. PubMed ID: 30558074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiome-metabolomic analysis of the impact of Zizyphus jujuba cv. Muzao polysaccharides consumption on colorectal cancer mice fecal microbiota and metabolites.
    Ji X; Hou C; Zhang X; Han L; Yin S; Peng Q; Wang M
    Int J Biol Macromol; 2019 Jun; 131():1067-1076. PubMed ID: 30926487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
    Jiang WR; Fang LP; Chang N; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
    Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
    Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.
    Bum Lee J; Huang Y; Oya Y; Nutzinger J; LE Ang Y; Sooi K; Chul Cho B; Soo RA
    Lung Cancer; 2024 Aug; 194():107862. PubMed ID: 38959670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.
    Shaikh FY; Gills JJ; Sears CL
    EBioMedicine; 2019 Oct; 48():642-647. PubMed ID: 31597596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer.
    Yang Y; Misra BB; Liang L; Bi D; Weng W; Wu W; Cai S; Qin H; Goel A; Li X; Ma Y
    Theranostics; 2019; 9(14):4101-4114. PubMed ID: 31281534
    [No Abstract]   [Full Text] [Related]  

  • 17. Allergen Immunization Induces Major Changes in Microbiota Composition and Short-Chain Fatty Acid Production in Different Gut Segments in a Mouse Model of Lupine Food Allergy.
    Andreassen M; Rudi K; Angell IL; Dirven H; Nygaard UC
    Int Arch Allergy Immunol; 2018; 177(4):311-323. PubMed ID: 30244242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Microbiota in Lung Cancer: Where Do We Stand?
    Georgiou K; Marinov B; Farooqi AA; Gazouli M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer.
    Qian X; Zhang HY; Li QL; Ma GJ; Chen Z; Ji XM; Li CY; Zhang AQ
    Clin Transl Med; 2022 Jun; 12(6):e947. PubMed ID: 35735103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
    Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
    Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.